Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s share price hit a new 52-week low on Friday. The company traded as low as C$0.85 and last traded at C$0.85, with a volume of 3,634 shares. The stock had previously closed at C$0.98.
Helix BioPharma Trading Down 16.3%
The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. The company’s fifty day moving average is C$1.41 and its 200-day moving average is C$1.54. The firm has a market capitalization of C$62.63 million, a P/E ratio of -20.50 and a beta of 1.15.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Further Reading
- Five stocks we like better than Helix BioPharma
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
